Floatz logo

cd123-car-nk cells

Relapse Leukemia

Chongqing Precision Biotech Co., LtdCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

124 Active assets in the Relapse Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB

View all 50 →

Same molecule, other indications

cd123-car-nk cells is also rated in:

Refractory LeukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
CD4+/CD56+ hematodermic neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →